Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Novartis Pharmaceuticals Corporation

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWITZERLAND Switzerland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              Boston Pharmaceuticals Licenses NASH Development Candidate from Novartis

              Contact the Supplier

              Lead Product(s): BOS-580

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BOS-580

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Boston Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement September 01, 2020

              Details:

              Under the terms of the agreement, Boston Pharmaceuticals will license worldwide development and commercial rights to the drug candidate BOS-580, for the treatment of Non-Alcoholic Steatohepatitis (NASH) from Novartis.

              EpiPharm

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWITZERLAND Switzerland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              CalciMedica Enters Research Pact with EpiPharma to Discover and Develop CRAC Channel Inhibitor Therapies

              Contact the Supplier

              Lead Product(s): CM5480

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM5480

              Highest Development Status: Preclinical Product Type: Undisclosed

              Partner/Sponsor/Collaborator: CalciMedica

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration July 21, 2020

              Details:

              CalciMedica to use EpiPharma’s state-of-the-art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate the discovery and development of CalciMedica’s CRAC channel inhibitor novel drug pipeline.

              PharmaCompass__DigitalAd